Patents by Inventor Brahmam Pujala

Brahmam Pujala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ATF6 INHIBITORS AND USES THEREOF
    Publication number: 20240124434
    Abstract: Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.
    Type: Application
    Filed: May 26, 2023
    Publication date: April 18, 2024
    Inventors: Jennifer ALFARO, Sebastian BELMAR, Gonzalo Esteban NÚÑEZ VASQUEZ, Brahmam PUJALA, Balaji Dashrath SATHE, Pooja THAKRAL, Rajesh Kumar PATIDAR, Sebastian BERNALES, Sarvajit CHAKRAVARTY
  • Inhibitors of fibroblast activation protein
    Patent number: 11780821
    Abstract: Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: October 10, 2023
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Jennifer Alfaro, Sebastian Belmar, Sebastian Bernales, Brahmam Pujala, Dayanand Panpatil, Bhawana Bhatt
  • Compounds and methods of use
    Patent number: 11702401
    Abstract: This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF?) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
    Type: Grant
    Filed: May 22, 2021
    Date of Patent: July 18, 2023
    Assignee: Medivation Technologies LLC
    Inventors: Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
  • INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN
    Publication number: 20230144841
    Abstract: Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
    Type: Application
    Filed: September 14, 2022
    Publication date: May 11, 2023
    Inventors: Brahmam PUJALA, Dayanand PANPATIL, Sebastian BERNALES, Sebastian BELMAR, Gonzalo Andrés URETA DÍAZ
  • GCN2 MODULATOR COMPOUNDS
    Publication number: 20230143059
    Abstract: The disclosures herein relate to novel compounds of Formula (1): or a salt thereof, wherein X, Y, R1, R2, R3, R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with General Control Nondepressible 2 (GCN2).
    Type: Application
    Filed: February 17, 2021
    Publication date: May 11, 2023
    Inventors: Balaji Dashrath SATHE, Brahmam PUJALA, Gonzalo Andrés URETA DÌAZ, Sebastian BERNALES, Jennifer BORTHWICK
  • SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS
    Publication number: 20230118115
    Abstract: This invention provides for substituted pyrazolo[3,4-d]pyrimidine compounds of the Formula (I): as Wee1 inhibitors. The substituted pyrazolo[3,4-d]pyrimidine compounds may find use as therapeutic agents for the treatment of diseases. The substituted pyrazolo[3,4-d]pyrimidine compounds may also find particular use in oncology.
    Type: Application
    Filed: May 12, 2022
    Publication date: April 20, 2023
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Brahmam PUJALA, Sanjeev SONI, Puja JAISWAL, Deepak PALVE, Varun KUMAR
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20230109104
    Abstract: Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: April 8, 2022
    Publication date: April 6, 2023
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Anil Kumar AGARWAL, Brahmam PUJALA, Sanjeev SONI, Satish K. ARYA, Deepak PALVE, Ashu GUPTA, Varun KUMAR
  • MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20230083885
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as modulators of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: April 1, 2022
    Publication date: March 16, 2023
    Inventors: Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Sebastian BERNALES, Sarvajit CHAKRAVARTY
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20230062022
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: October 1, 2021
    Publication date: March 2, 2023
    Inventors: Son Minh PHAM, Sarvajit Chakravarty, Jayakanth Kankanala, Brahmam Pujala, Amit Shete, Bhawana Bhatt, Anil Kumar Agarwal, Sanjeev Soni, Jiyun Chen
  • INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20230047589
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: August 10, 2021
    Publication date: February 16, 2023
    Inventors: Sebastian BERNALES, Luz Marina DELGADO OYARZO, Gonzalo Esteban NÚÑEZ VASQUEZ, Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Bhawana BHATT, Sarvajit CHAKRAVARTY
  • MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20230042881
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as modulators of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: June 3, 2022
    Publication date: February 9, 2023
    Inventors: Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Sebastian BERNALES, Sarvajit CHAKRAVARTY
  • ATF6 MODULATORS AND USES THEREOF
    Publication number: 20230028584
    Abstract: Compounds (1-2) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.
    Type: Application
    Filed: October 9, 2020
    Publication date: January 26, 2023
    Inventors: Brahmam PUJALA, Balaji Dashrath SATHE, Sebastian BERNALES, Gonzalo Andrés URETA DÍAZ, Sebastian BELMAR
  • ATF6 MODULATORS AND USES THEREOF
    Publication number: 20220389001
    Abstract: Compounds (I) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.
    Type: Application
    Filed: October 9, 2020
    Publication date: December 8, 2022
    Inventors: Brahmam PUJALA, Balaji Dashrath SATHE, Pooja THAKRAL, Sebastian BERNALES, Gonzalo Andrés URETA DÍAZ, Sebastian BELMAR
  • Inhibitors of fibroblast activation protein
    Patent number: 11504364
    Abstract: Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
    Type: Grant
    Filed: December 21, 2019
    Date of Patent: November 22, 2022
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Brahmam Pujala, Dayanand Panpatil, Sebastian Bernales, Sebastian Belmar, Gonzalo Andrés Ureta Díaz
  • COMPOUNDS AS LXR AGONISTS
    Publication number: 20220363662
    Abstract: The present invention generally discloses compounds having LXR (the liver X receptor) agonistic activity, to the use of such compounds in the treatment of various disorders such as proliferative disorders, Alzheimer's disease, inflammatory diseases, and diseases characterized by defects in cholesterol and lipid metabolism. Specifically, the present invention discloses compound of formula (IA) which exhibit LXR agonist activity, specifically to LXR?. The invention also discloses method of synthesis of said compounds, method of using said compounds, pharmaceutical compositions comprising said compounds and method of using thereof.
    Type: Application
    Filed: April 20, 2022
    Publication date: November 17, 2022
    Inventors: Brahmam Pujala, Balaji Dashrath Sathe, Abhinandan Danodia, Ashu Gupta, Sanjeev Soni, Vivek Kumar, Amantullah Ansari, Farha Khan, Arindam Sarkar, Pavan V. Payghan
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20220347187
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: August 13, 2020
    Publication date: November 3, 2022
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Jiyun CHEN, Brahmam PUJALA, Bhawana BHATT, Mukesh GANGAR, Amit S. SHETE
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20220281859
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 8, 2022
    Applicant: Nuvation Bio Inc.
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Jiyun CHEN, Brahmam PUJALA, Bhawana BHATT, Mukesh GANGAR, Amit S. SHETE
  • ARYL HYDROCARBON RECEPTOR ACTIVATORS
    Publication number: 20220281824
    Abstract: Small molecule AhR ligands are disclosed. The ligands can induce the differentiation of Tr1 cells to suppress pathogenic immune responses without inducing nonspecific immune suppression. Methods of treatment of autoimmune diseases using the AhR ligands are also disclosed.
    Type: Application
    Filed: July 30, 2020
    Publication date: September 8, 2022
    Applicant: Oregon State University
    Inventors: Siva Kumar Kolluri, Nancy I. Kerkvliet, Sebastian Bernales, Jit Chakravarty, Brahmam Pujala, Pasha Khan, Varun Kumar, Abhinandan Danodia, Gonzalo Ureta
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20220273659
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: July 1, 2020
    Publication date: September 1, 2022
    Inventors: Son Minh PHAM, Sarvajit CHAKRAVARTY, Jayakanth KANKANALA, Brahmam PUJALA, Amit SHETE, Mukesh GANGAR, Bhawana BHATT, Chris P. MILLER, Jeremy D. PETTIGREW
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20220220115
    Abstract: Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: April 8, 2020
    Publication date: July 14, 2022
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Brahmam PUJALA, Sanjeev SONI, Puja JAISWAL, Deepak PALVE, Varun KUMAR